Pfizer

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Pfizer sits in the top decile of US sponsors by registered trial count (#7 of 15,742 sponsors by registered trial count).

1,845 total trials 106 currently recruiting 1335 completed early-phase tilt top decile by trial count

Pfizer: 1,845 sponsored US clinical trials, 106 recruiting.

Pfizer sponsors 1,845 registered US clinical trials on ClinicalTrials.gov, 106 of them currently recruiting, and 1,335 completed. 504 of these trials are in Phase 3-4 (later-stage) and 1,173 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 44 trials.

Top-decile sponsor footprint

Pfizer ranks in the top decile of sponsors by registered trial count (#7 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 39/100

1,335 of 1,673 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (79.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,845 total, page 20 of 37

COMPLETED Phase 1

Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer

NCT01597193

COMPLETED Phase 2

Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain

NCT01559259

COMPLETED Phase 2

A Study of ARRY-502 in Patients With Persistent Asthma

NCT01561690

COMPLETED Phase 2

Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Tiotropium Bromide

NCT01543919

COMPLETED Phase 1

A Study To Compare Pharmacokinetics Of Dacomitinib (PF-00299804) Between Healthy Subjects And Subjects With Mild And Moderate Hepatic Impairment

NCT01571388

COMPLETED Phase 2

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

NCT01470599

COMPLETED Phase 3

A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis

NCT01465763

COMPLETED Phase 1

A Study To Evaluate The Effect Of CP-690,550 On Measures Of Kidney Function In Patients With Active Rheumatoid Arthritis

NCT01484561

COMPLETED Phase 2

Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer

NCT01547299

COMPLETED Phase 2

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

NCT01526057

COMPLETED Phase 2

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

NCT01393899

COMPLETED Phase 1

Pharmacokinetics Study of ALO-02 and OxyContin

NCT01557257

COMPLETED Phase 3

Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections

NCT01499290

COMPLETED Phase 1

Effect of Linezolid on Ex Vivo Neutrophil and Monocyte Function in Healthy Males

NCT01544673

COMPLETED Phase 1

A Study To Evaluate The Effects Of PF-05175157 In Healthy Volunteers

NCT01537497

COMPLETED Phase 3

A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD

NCT01371708

COMPLETED Phase 3

A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD

NCT01371721

COMPLETED Phase 2

Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin

NCT01517373

COMPLETED Phase 1

A Study to Assess the Levels of CAZ-AVI and Metronidazole in the Blood When Given Together and Separately

NCT01534247

COMPLETED Phase 3

A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin

NCT01473407

COMPLETED Phase 1

Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer

NCT01565928

TERMINATED Phase 2

A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer

NCT01420081

COMPLETED Phase 3

A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin

NCT01473420

COMPLETED Phase 1

A Study to Assess the Relative Bioavailability of a Modified-Release Formulation of PF-05180999

NCT01530529

TERMINATED Phase 1

A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy

NCT01488877

COMPLETED Phase 2

Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO

NCT01465802

COMPLETED Phase 2

Efficacy Of PF-05089771 In Treating Postoperative Dental Pain

NCT01529346

COMPLETED Phase 2

Safety and Efficacy of EXC 001 in Subjects Who Have Participated in Prior Studies of EXC 001

NCT01494922

COMPLETED Phase 1

A 2-week Trial Of PF-04991532 In Patients With Type 2 Diabetes

NCT01469065

COMPLETED Phase 2

Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus

NCT01405196

TERMINATED Phase 2

PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma

NCT01441414

COMPLETED Phase 3

A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

NCT01372150

COMPLETED Phase 1

A Study To Estimate The Effect Of Repeated Dosing of PF-05175157 On The Pharmacokinetics Of A Single Dose Of Simvastatin In Healthy Adult Subjects

NCT01469468

COMPLETED Phase 1

A Study to Evaluate The Pharmacokinetics Of Crizotinib (PF-02341066) In Subjects With Impaired Renal Function

NCT01419041

COMPLETED Phase 4

Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders

NCT01456936

COMPLETED Phase 1

Study to Evaluate the PK of BMS-927711 in Patient With Migraine During Acute Migraine and Non-migraine Condition

NCT01445067

COMPLETED Phase 1

Single Dose Study To Study The Absorption, Metabolism And Excretion Of PF-04991532

NCT01469481

COMPLETED Phase 2

Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes

NCT01475461

TERMINATED Phase 1

A Single Dose Study Of PF-06291874 In Healthy Adult Subjects

NCT01499017

TERMINATED Phase 1

A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus

NCT01470313

COMPLETED Phase 1

A Study To Estimate The Effect Of Ketoconazole On The Pharmacokinetics Of Pf-04937319 In Healthy Subjects

NCT01468714

COMPLETED Phase 1

Pharmacokinetics and Bioequivalence of Vycavert (10 mg Hydrocodone Bitartrate/325 mg Acetaminophen) Compared to the Reference Drug Norco

NCT01456520

COMPLETED

Non-Interventional Retrospective Correlation Of Tumor Mutational Status To Clinical Benefit Of GIST Patients Treated With Sunitinib

NCT01459757

COMPLETED Phase 2

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

NCT01393626

COMPLETED Phase 1

Healthy Volunteers Study to Estimate the Effects of Food on the Bioavailability of Oxycodone and Naltrexone/6- Β -Naltrexol From a Extended Release Formulation of Oxycodone With Sequestered Naltrexone

NCT01456507

COMPLETED Phase 1

A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 (RN316) in Subjects With Hypercholesterolemia

NCT01435382

COMPLETED Phase 1

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study Of PF-04427429 In Healthy Women Volunteers

NCT01511497

COMPLETED Phase 2

Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine

NCT01430442

COMPLETED Phase 4

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)

NCT01432457

TERMINATED Phase 2

Efficacy Of Pf-04531083 In Treating Post-Surgical Dental Pain

NCT01512160

← Previous Page 20 of 37 Next →

Phase Distribution

PhaseTrial count
Phase 1 703
Phase 2 470
Phase 3 411
Phase 4 93

What is open in the Pfizer pipeline

106 recruiting of 1,845 indexed (6% open); 1,335 completed (72%).

Phase mix: 504 late (III/IV) vs 1,173 early (I/II) (early-phase heavy).

Top condition: Healthy (44 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Pfizer: open-pipeline peers nationwide

Peers matched on 1,845 registered trials and 6% open enrollment, not the therapeutic-area sidebar.

Pfizer sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,5002,000 5%10%15%20% Total trials Recruiting share PfizerMemorial Sloan Kettering Cancer CenterStanford UniversityDuke UniversityUniversity of California, San FranciscoPacira PharmaceuticalsBioDelivery Sciences InternationalColgate PalmoliveDurham VA Medical Center
Pfizer sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Pfizer sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,845 trials (± recruiting share)

Sponsors near 6% open enrollment (± trial volume)

What to do with this Pfizer page

1,845 registered trials is a research-attention snapshot, not an endorsement of Pfizer or any single study.

  • 106 of Pfizer's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Healthy is the condition Pfizer studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Pfizer pipeline card: 1,845 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.